Recruiting studies: Melanoma And Brain Metastases

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases
Phase 2 · 1 location(s) · Sheba Medical Center · NCT05909618 Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Mela
Phase 3 · 15 location(s) · ETOP IBCSG Partners Foundation · NCT05522660 Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to
Phase 3 · 270 location(s) · NRG Oncology · NCT06500455 Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
Phase 2 · 1 location(s) · Stanford University · NCT06712927 Palbociclib and Pembrolizumab In Central Nervous System Metastases
Phase 2 · 2 location(s) · Massachusetts General Hospital · NCT02896335 Melanoma Metastasized to the Brain and Steroids
Phase 2 · 3 location(s) · Inge Marie Svane · NCT03563729 Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
Phase 2 · 9 location(s) · Melanoma Institute Australia · NCT03340129 Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases
Phase 1/Phase 2 · 1 location(s) · Melanoma and Skin Cancer Trials Limited · NCT06163820 Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/Phase 2 · 7 location(s) · Neonc Technologies, Inc. · NCT06047379 Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to
Phase 1/Phase 2 · 1 location(s) · Kari Kendra · NCT05588453 Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases
NA · 1 location(s) · The Netherlands Cancer Institute · NCT07511933 Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutan
Phase 1/Phase 2 · 2 location(s) · University of Utah · NCT06194929 Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic B
Phase 2 · 18 location(s) · Grupo Español Multidisciplinar de Melanoma · NCT06887088 Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05704647 Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Phase 2 · 2 location(s) · Brigham and Women's Hospital · NCT04899908 A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V60
Phase 2 · 331 location(s) · SWOG Cancer Research Network · NCT04511013

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.